AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04128696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is available as an intravenous infusion.
Study NCT04128696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is available as an intravenous infusion.
Study NCT01571635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOTATERCEPT (ACE-011)
Description: 0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.
Study NCT01935531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% diclofenac in 2.5% hyaluronic acid gel
Study NCT02096029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) Sampling
Description: 2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
Study NCT02096029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ask, Advise, Refer (physician brief advice)
Study NCT03570580 — intervention group
Intervention type: OTHER
Intervention: OSA scoring
Description: OSA scoring (four scores: STOP-Bang, P-SAP, OSA50, DES-OSA were performed by several scorers on each patients, after what agreement between scores will be evaluated).
Study NCT00822263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Description: Anti-oxidant in a pill format
Study NCT00822263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control for study
Study NCT02113969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Pessary
Description: Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
Study NCT04264559 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Infrared thermal imaging
Description: A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.
Study NCT04264559 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Infrared thermal imaging
Description: A thermal imager is used to record thermal images.The baseline temperature of relevant acupoints or sites on the Heart and Lung meridians will be measured.
Study NCT04264559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: Two sessions of moxibustion intervention will be performed in the Heart meridian and Lung meridian successively. During moxibustion, the temperature change of relevant acupoints or sites in the Heart and Lung meridians will be measured by infrared thermal imaging.~* Intervention in the Heart meridian: moxibustion will be performed in acupoint HT3 of the Heart meridian for 15 minutes.~* Intervention in the Lung meridian: moxibustion will be performed in acupoint LU5 of the Lung meridian for 15 minutes.
Study NCT04494178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2.0g G-PUR®
Description: Oral administration (Intervention period I)
Study NCT04494178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2.0g G-PUR®
Description: Oral administration (Intervention period II)
Study NCT04494178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention period I
Study NCT04494178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention period II
Study NCT01757366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginsenoside Rg3 plus First-line Chemotherapy
Description: Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
Study NCT01757366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First-line Chemotherapy
Description: XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
Study NCT00642031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triciribine
Description: 15 mg/m\^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
Study NCT03712137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOLUX XC
Description: Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
Study NCT03712137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-treatment control
Description: No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.
Study NCT04384926 — intervention group
Intervention type: PROCEDURE
Intervention: Elective Cancer Surgery
Description: Planned, curative cancer surgery
Study NCT00490737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin
Description: 6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
Study NCT01990066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Exercise
Description: Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
Study NCT02353429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Description: Patients will receive 60 mg daily and then 180 daily in case of progression
Study NCT02544100 — intervention group
Intervention type: OTHER
Intervention: Database Entry/Biospecimen Collection
Description: blood, urine, CFS samples and medical data collected
Study NCT03997331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CRx Health
Description: CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).
Study NCT03997331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRx Health
Description: CRx Health is a connected health solution comprised of connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer) paired to a mobile smartphone app (CRx Health).
Study NCT03997331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronicare
Description: Chronicare is a disease management program comprising self-management data from the CRx Health solution syncing to an automated support system (Intervention Engine) and a remote care application (CRx Care) used by a team of clinicians to remotely monitor and support patients.
Study NCT00196222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF-ablation
Description: RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
Study NCT00196222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryo ablation
Description: Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
Study NCT03627182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 0.5mg
Description: CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
Study NCT03627182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study).
Study NCT03888716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL1333
Description: 25 and 100 mg KL1333 encapsulated tablets
Study NCT03888716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 25 and 100 mg placebo encapsulated tablets
Study NCT03793595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seated Battle Ropes Protocol
Description: Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.
Study NCT03793595 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seated Upper Extremity Arm Bike
Description: A modified Young Men's Christian Association (YMCA) cycle test will be performed.
Study NCT04202354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HSD Injection
Description: single or multiple doses of ARO-HSD by subcutaneous (sc) injections
Study NCT04202354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile normal saline (0.9% NaCl)
Description: calculated volume to match active treatment, by sc injection
Study NCT01089049 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FemMED Breast Health Formula
Description: Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
Study NCT00591253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT00591253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil
Description: Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
Study NCT00591253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
Study NCT01160198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous ascorbate
Description: 100 mg elemental iron
Study NCT01160198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous bisglycinate chelate 1 OD
Description: 60 mg elemental iron
Study NCT01160198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous bisglycinate chelate 2 OD
Description: 120 mg elemental iron
Study NCT03341598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF
Description: Periodontal surgical technique to treat gingival recessions.
Study NCT03341598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: Periodontal surgical technique to treat gingival recessions.
Study NCT03341598 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: Restorative procedure to treat tooth structure loss.
Study NCT03341598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R
Description: Restorative procedure to treat tooth structure loss.
Study NCT03341598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MC
Description: Xenogenous graft placed in the surgical site.
Study NCT04039165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PP-MI Intervention
Description: The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
Study NCT04363736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tociliuzumab
Description: Participants will receive IV TCZ.
Study NCT04363736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tociliuzumab
Description: Participants will receive IV TCZ.
Study NCT00142454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Patients applied imiquimod cream at bedtime every day for 5 consecutive days (for the first 5 days of Cycles 1-3 and for the first 4 days of Cycle 4) at a dose of 250 mg as supplied in single-use packets to a 4 x 5 cm area of healthy skin, alternating among the extremities (upper inner arms and inner thighs) in each cycle. The cream was to be rubbed into the skin until it was no longer visible. Patients were encouraged to wash their hands before and after applying cream. The application site was not occluded. The next morning, 6 to 10 hours after initial application, the treated area was washed with mild soap and water to remove any residual cream.
Study NCT00142454 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein
Description: NY-ESO-1 protein was injected intradermally by a study physician or nurse at a dose of 100 μg into the imiquimod-pretreated area on Day 3 of each cycle for 4 consecutive 21-day cycles.
Study NCT02289391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia maintenance
Description: * Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60.
Study NCT00505128 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic sphincterotomy
Description: procedure
Study NCT03008629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Podofix nail brace
Description: Podofix nail brace
Study NCT03008629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combiped nail brace
Description: Combiped nail brace
Study NCT03008629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Podofix and then Combiped nail brace
Description: Podofix and then Combiped nail brace
Study NCT03351413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LIVE-LiFE to Prevent Falls Among Older Fallers
Description: LIVE-LiFE Intervention: Individually tailored program at the participant's home spaced across 12 weeks including:~* Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~* Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~* Medication review and feedback concerning medications with increased fall risk~Measurement intervals: Baseline, 4 months, 8 months (with $25 gift card given at each visit for your time)
Study NCT00251771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter-directed venous thrombolysis
Description: catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
Study NCT01308983 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amiloride
Description: Amiloride 10 mg orally once a day for 16 weeks
Study NCT00003299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT00003299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00003299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study NCT00003299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT04567199 — intervention group
Intervention type: OTHER
Intervention: Observational, retrospective
Description: retrospective analysis of observed results, for both study groups.
Study NCT02289391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia maintenance
Description: * Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60.
Study NCT02289391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Assisted anesthesia
Description: Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
Study NCT03013010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-Gimeracil-Oteracil Potassium
Description: The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
Study NCT03013010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-Gimeracil-Oteracil Potassium
Description: The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
Study NCT03013010 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks.
Study NCT03013010 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric resection
Description: A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
Study NCT03013010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric resection
Description: A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
Study NCT03013010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Study NCT03013010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Study NCT02220972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Study NCT02220972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04304833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Provider-Based Care Model Arm
Description: The PI will be supplementing standard care by providing and training each patient in the use of an analog (not internet connected) vital sign kit for 6 months: weight scale, blood pressure cuff, pulse oximeter. A Log for recording their vital sign measures.
Study NCT04304833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Model Arm
Description: The PI will provide each patient with weight scale, blood pressure cuff, \& pulse oximeter kit connected to a Bluetooth-paired Android Health Tablet for 6 months. Daily vital sign readings will be sent to the secure cloud-based software. If the readings are out-of-range, the Registered Nurse Call Center will be automatically alerted and triaged.
Study NCT03776136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Administered orally once a day during each 21-day cycle.
Study NCT03776136 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W.
Study NCT00655980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 and folic acid
Description: 1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
Study NCT00655980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrous oxide and placebo
Study NCT00655980 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Study NCT01953796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene
Description: For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
Study NCT01953796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene
Description: For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.